发布求助
文献互助 智能选刊 最新文献

Neurodegenerative disease management最新文献

筛选
英文 中文
Exploring the impact of caring for an individual with neurogenic orthostatic hypotension: a qualitative study. 探讨神经源性直立性低血压患者护理的影响:一项定性研究。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-06-01 DOI: 10.2217/nmt-2022-0016
Katy Gallop, Ngan Pham, Grant Maclaine, Emma Saunders, Bonnie Black, Sarah Acaster
{"title":"Exploring the impact of caring for an individual with neurogenic orthostatic hypotension: a qualitative study.","authors":"Katy Gallop,&nbsp;Ngan Pham,&nbsp;Grant Maclaine,&nbsp;Emma Saunders,&nbsp;Bonnie Black,&nbsp;Sarah Acaster","doi":"10.2217/nmt-2022-0016","DOIUrl":"https://doi.org/10.2217/nmt-2022-0016","url":null,"abstract":"<p><p><b>Aim:</b> This study aimed to explore the impact of caring for an individual with neurogenic orthostatic hypotension (nOH). <b>Methods:</b> Informal caregivers of individuals with nOH and either Parkinson's disease, multiple system atrophy, pure autonomic failure or dementia with Lewy bodies completed semi-structured interviews. Data were analyzed using thematic analysis; the identified concepts were used to develop a conceptual model. <b>Results:</b> Twenty informal caregivers were interviewed. Analysis identified several areas of caregiver impact due to nOH including impact on their time, particularly a need to supervise the patient to prevent falls as well as a lack of freedom and negative physical, work and social impacts. Many reported negative emotional impacts, including worry, stress or fear about the patient falling, depression and frustration. The conceptual model shows the relationships between concepts. <b>Conclusion:</b> The results highlight the wide-ranging impact of nOH, and the specific impact of the fear of falls on informal caregivers' lives.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 3","pages":"191-201"},"PeriodicalIF":2.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10041184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cross-sectoral collaboration among hospital professionals on rehabilitation for patients with neuromuscular diseases. 医院专业人员在神经肌肉疾病患者康复方面的跨部门合作。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-06-01 DOI: 10.2217/nmt-2022-0024
Charlotte Handberg, Ulla Werlauff
{"title":"Cross-sectoral collaboration among hospital professionals on rehabilitation for patients with neuromuscular diseases.","authors":"Charlotte Handberg,&nbsp;Ulla Werlauff","doi":"10.2217/nmt-2022-0024","DOIUrl":"https://doi.org/10.2217/nmt-2022-0024","url":null,"abstract":"<p><p><b>Introduction:</b> Living with a neuromuscular disease often leads to a need for specialized rehabilitation due to the complexity and progression of the diseases. <b>Aim:</b> To investigate cross-sectoral collaboration on rehabilitation for patients with neuromuscular diseases among hospital professionals to inform future targeted rehabilitation services. <b>Patients & methods:</b> The design was qualitative using the interpretive description methodology and the theoretical lens of symbolic interactionism. Ethnographic fieldwork was conducted, and 50 hospital professionals included, 19 of whom were interviewed. <b>Results & conclusion:</b> The results emphasize the importance of relations when collaborating across sectors. The professionals acted and made choices in relation to dilemmas and influences of diagnosis and progression, professional demarcations in multiprofessional teams, and cross-sectoral collaboration toward a mutual goal.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 3","pages":"161-175"},"PeriodicalIF":2.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The amyloid-β pathway in Alzheimer's disease: a plain language summary. 阿尔茨海默病中的淀粉样蛋白-β通路：通俗易懂的摘要。
IF 2.3
Neurodegenerative disease management Pub Date : 2023-06-01 Epub Date: 2023-03-30 DOI: 10.2217/nmt-2022-0037
Harald Hampel, Yan Hu, John Hardy, Kaj Blennow, Christopher Chen, George Perry, Seung Hyun Kim, Victor L Villemagne, Paul Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Colin L Masters, Min Cho, Lars Lannfelt, Jeffrey L Cummings, Andrea Vergallo
{"title":"The amyloid-β pathway in Alzheimer's disease: a plain language summary.","authors":"Harald Hampel, Yan Hu, John Hardy, Kaj Blennow, Christopher Chen, George Perry, Seung Hyun Kim, Victor L Villemagne, Paul Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Colin L Masters, Min Cho, Lars Lannfelt, Jeffrey L Cummings, Andrea Vergallo","doi":"10.2217/nmt-2022-0037","DOIUrl":"10.2217/nmt-2022-0037","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This plain language summary of an article published in <i>Molecular Psychiatry</i>, reviews the evidence supporting the role of the amyloid-β (Aβ) pathway and its dysregulation in Alzheimer's disease (AD), and highlights the rationale for drugs targeting the Aβ pathway in the early stages of the disease.</p><p><strong>Why is this important?: </strong>Aβ is a protein fragment (or peptide) that exists in several forms distinguished by their size, shape/structure, degree of solubility and disease relevance. The accumulation of Aβ plaques is a hallmark of AD. However, smaller, soluble aggregates of Aβ - including Aβ protofibrils - also play a role in the disease. Because Aβ-related disease mechanisms are complex, the diagnosis, treatment and management of AD should be reflective of and guided by up-to-date scientific knowledge and research findings in this area. This article describes the Aβ protein and its role in AD, summarizing the evidence showing that altered Aβ clearance from the brain may lead to the imbalance, toxic buildup and misfolding of the protein - triggering a cascade of cellular, molecular and systematic events that ultimately lead to AD.</p><p><strong>What are the key takeaways?: </strong>The physiological balance of brain Aβ levels in the context of AD is complex. Despite many unanswered questions, mounting evidence indicates that Aβ has a central role in driving AD progression. A better understanding of the Aβ pathway biology will help identify the best therapeutic targets for AD and inform treatment approaches.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 3","pages":"141-149"},"PeriodicalIF":2.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e1/70/nmt-13-141.PMC10334247.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9775627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wearable activity monitors to support physical activity interventions in neurodegenerative disease: a feasibility study. 可穿戴活动监测仪支持神经退行性疾病的身体活动干预:可行性研究
IF 2.6
Neurodegenerative disease management Pub Date : 2023-06-01 DOI: 10.2217/nmt-2022-0028
Hai-Jung Steffi Shih, Lori Quinn, Philippa Morgan-Jones, Katrina Long, Abigail R Schreier, Ciaran P Friel
{"title":"Wearable activity monitors to support physical activity interventions in neurodegenerative disease: a feasibility study.","authors":"Hai-Jung Steffi Shih,&nbsp;Lori Quinn,&nbsp;Philippa Morgan-Jones,&nbsp;Katrina Long,&nbsp;Abigail R Schreier,&nbsp;Ciaran P Friel","doi":"10.2217/nmt-2022-0028","DOIUrl":"https://doi.org/10.2217/nmt-2022-0028","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate the feasibility of using activity monitors in a physical activity (PA) intervention in people with Parkinson's (PD) and Huntington's disease (HD). <b>Materials & methods:</b> People with early-stage PD (n = 13) and HD (n = 14) enrolled in a 4-month coaching program, wore a Fitbit, and were guided through a behavioral intervention to facilitate PA uptake. Wear time, wear habits and activity metrics (e.g., steps) were analyzed. <b>Results:</b> Retention rate was 85% and participants had an average 92.3% (±9.2) valid wear days. Daily wear time was 18.4 (±4.5) h. Day & night Fitbit wearers showed improvements in steps (d = 1.02) and MET×min/week (d = 0.69) compared with day-only wearers. <b>Conclusion:</b> Implementing wearables in a coaching intervention was feasible and provided insights into PA behavior.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 3","pages":"177-189"},"PeriodicalIF":2.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon β-1a users. 患者报告的结果是肌内干扰素β-1a使用者疾病失能的最强预测因子。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-06-01 DOI: 10.2217/nmt-2022-0008
Caila B Vaughn, Katelyn S Kavak, Dejan Jakimovski, Natasha Qutab, Robin Avila, Megan Vignos, Bianca Weinstock-Guttman
{"title":"Patient-reported outcomes are the strongest predictors of disease disability in intramuscular interferon β-1a users.","authors":"Caila B Vaughn,&nbsp;Katelyn S Kavak,&nbsp;Dejan Jakimovski,&nbsp;Natasha Qutab,&nbsp;Robin Avila,&nbsp;Megan Vignos,&nbsp;Bianca Weinstock-Guttman","doi":"10.2217/nmt-2022-0008","DOIUrl":"https://doi.org/10.2217/nmt-2022-0008","url":null,"abstract":"<p><p><b>Introduction:</b> Patient-reported outcomes (PROs) are valuable measures for routine clinical care of people with multiple sclerosis (pwMS). <b>Materials:</b> 646 pwMS treated with interferon-β-1a (IFN-β-1a) were retrospectively included from the New York State Multiple Sclerosis Consortium. Clinical and PRO data at enrollment and 3 year follow-up were collected. PwMS with stable disease and disability worsening were matched (1:1) based on age, Expanded Disability Status Scale (EDSS) scores and disease duration. Disability worsening was determined based on trial criteria. <b>Results:</b> PwMS with future EDSS worsening had higher baseline and follow-up timed-25-foot walk (6.6 vs 5.5 s; 9.1 vs 5.5 s; p < 0.001) when compared with stable pwMS. Worsening pwMS reported higher baseline difficulties in getting up (odds ratio [OR] = 2.4; p = 0.009), climbing stairs (OR = 1.6; p = 0.024) and standing (OR = 2.2; p < 0.001). Worsening pwMS reported greater lower limb limitations (OR = 2.3; p = 0.004) and fatigue (OR = 1.8; p = 0.002). <b>Conclusion:</b> Higher fatigue and lower limb functional limitations are significant predictors of future disability worsening in pwMS.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 3","pages":"151-159"},"PeriodicalIF":2.6,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9672864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
5-HT1A agonists for levodopa-induced dyskinesia in Parkinson's disease. 5-HT1A激动剂治疗帕金森病左旋多巴诱导的运动障碍。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2022-0039
Jawad Al-Kassmy, Christine Sun, Philippe Huot
{"title":"5-HT<sub>1A</sub> agonists for levodopa-induced dyskinesia in Parkinson's disease.","authors":"Jawad Al-Kassmy,&nbsp;Christine Sun,&nbsp;Philippe Huot","doi":"10.2217/nmt-2022-0039","DOIUrl":"https://doi.org/10.2217/nmt-2022-0039","url":null,"abstract":"<p><p>Levodopa is the most effective agent for treating the symptoms of Parkinson's disease (PD). However, levodopa-induced dyskinesia remains a significant complication that manifests after few years of treatment, for which therapeutic options remain limited. Several agonists of the serotonin type 1A (5-HT<sub>1A</sub>) receptor with varying levels of efficacy and interaction at other sites, have been tested in the clinic. Clinical trials testing 5-HT<sub>1A</sub> agonists have yielded inconsistent results in alleviating dyskinesia, especially that the antidyskinetic benefit observed was often accompanied by an adverse effect on motor function. In this article, we summarize and analyze the various clinical trials performed with 5-HT<sub>1A</sub> agonists in PD patients with dyskinesia and offer perspectives on the future of this class of agents in PD.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"101-112"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9575481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early approaches of YKL-40 as a biomarker and therapeutic target for Parkinson's disease. YKL-40作为帕金森病生物标志物和治疗靶点的早期研究
IF 2.6
Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2022-0010
Mai M Anwar, Mohamed H Fathi
{"title":"Early approaches of YKL-40 as a biomarker and therapeutic target for Parkinson's disease.","authors":"Mai M Anwar,&nbsp;Mohamed H Fathi","doi":"10.2217/nmt-2022-0010","DOIUrl":"https://doi.org/10.2217/nmt-2022-0010","url":null,"abstract":"<p><p><b>Aim:</b> To investigate whether the estimation of cerebrospinal fluid (CSF) and brain YKL-40 levels may be used as an efficient biomarker for Parkinson's disease (PD). <b>Methods:</b> Lipopolysaccharides (LPS) was injected into the right substantia nigra <i>pars compacta</i> (SNpc). Rats were divided into: control group, early LPS-induced PD group (14 days), and advanced LPS-induced PD group (28 days). YKL-40 and other related factors were detected in CSF and brain tissue. <b>Results:</b> Increased expression of YKL-40 was observed in brain tissue and CSF of PD-induced rats associated with triggered inflammatory cytokine release. <b>Conclusion:</b> The current study was limited to detecting YKL-40 and other inflammatory factors in brain and CSF. YKL-40 may be considered as an early biomarker and therapeutic target for PD.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"85-99"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9942185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Interview with Nobutaka Hattori: a life researching Parkinson's disease pathogenesis. 专访服部信孝:研究帕金森病发病机制的一生。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2023-0010
Nobutaka Hattori
{"title":"Interview with Nobutaka Hattori: a life researching Parkinson's disease pathogenesis.","authors":"Nobutaka Hattori","doi":"10.2217/nmt-2023-0010","DOIUrl":"https://doi.org/10.2217/nmt-2023-0010","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"71-73"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9624822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parkinson's disease research in Morocco: a review. 摩洛哥帕金森病研究综述
IF 2.6
Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2022-0021
Mohamed Daghi, Abdelhakim Lakhdar, Hicham El Otmani
{"title":"Parkinson's disease research in Morocco: a review.","authors":"Mohamed Daghi,&nbsp;Abdelhakim Lakhdar,&nbsp;Hicham El Otmani","doi":"10.2217/nmt-2022-0021","DOIUrl":"https://doi.org/10.2217/nmt-2022-0021","url":null,"abstract":"<p><p><b>Aim:</b> To quantify and provide an overview on the scientific productivity made by Moroccan academics in the research on Parkinson's disease (PD) and parkinsonism. <b>Materials & methods:</b> Scientific articles, in either English or French, were gathered from published literature in three recognized databases: PubMed, ScienceDirect and Scopus. <b>Results:</b> We identified 95 published papers from which 39 articles have been extracted after removing inadequate publications and duplications between databases. All articles were published between 2006 and 2021. The selected articles were subdivided into five categories. <b>Conclusion:</b> The Moroccan academia is presently facing a low productivity issues and a lack of research laboratories focusing on PD research. We anticipate that providing more budgetary funds will significantly improve the productivity of PD research.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"129-139"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes. 阿波啡舌下膜和左旋多巴对OFF发作患者的运动反应。
IF 2.6
Neurodegenerative disease management Pub Date : 2023-04-01 DOI: 10.2217/nmt-2022-0038
Stuart H Isaacson, Alyssa Bowling, Ian Zhang, Eric Pappert, Fabrizio Stocchi
{"title":"Motor response with apomorphine sublingual film and levodopa in patients with OFF episodes.","authors":"Stuart H Isaacson,&nbsp;Alyssa Bowling,&nbsp;Ian Zhang,&nbsp;Eric Pappert,&nbsp;Fabrizio Stocchi","doi":"10.2217/nmt-2022-0038","DOIUrl":"https://doi.org/10.2217/nmt-2022-0038","url":null,"abstract":"<p><p><b>Aim:</b> Evaluate timing of motor improvement with carbidopa/levodopa (CD/LD) and apomorphine sublingual film (SL-APO) in patients with Parkinson's disease and OFF episodes. <b>Methods:</b> A <i>post hoc</i> pooled analysis from two studies assessed Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) scores and investigator-rated FULL ON. <b>Results:</b> At 15 and 30 min following the prescribed first daily CD/LD dose, mean improvements in MDS-UPDRS-III scores were -6.7 and -16.3, respectively, and FULL ON was achieved by 6.5 and 41.8% of patients. Following an optimized SL-APO dose, mean improvements in MDS-UPDRS-III scores were -13.9 and -22.9, and FULL ON was achieved by 34.7 and 81.0% of patients. <b>Conclusion:</b> Concomitant administration of SL-APO with carbidopa/levodopa may be useful for delayed ON.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"13 2","pages":"75-84"},"PeriodicalIF":2.6,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9623349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信